Oak-backed Artis BioSolutions to acquire Landmark Bio.

Oak-backed Artis BioSolutions, a company founded to streamline the discovery, development and production of genetic medicines, agreed to acquire Landmark Bio, a cell and gene therapy manufacturing company. Financial terms were not disclosed. “Landmark Bio was born from a bold vision shared by our founding partners – to remove barriers in the manufacturing of advanced therapies and accelerate the development of life-changing medicines. In just a few short years, we’ve built a world-class team and capabilities that have become a vital force in the life sciences innovation ecosystem. Joining Artis BioSolutions marks an exciting new chapter for Landmark Bio. Together, we will stay true to our mission as we scale our operations to bring breakthrough therapies to more patients,” Ran Zheng, Landmark Bio CEO.